References
- PawelecGAge and immunity: what is “immunosenescence”?Exp Gerontol20181054929111233
- VenturaMTCasciaroMGangemiSBuquicchioRImmunosenescence in aging: between immune cells depletion and cytokines up-regulationClin Mol Allergy2017152129259496
- BoltonCSmithPAThe influence and impact of ageing and immunosenescence (ISC) on adaptive immunity during multiple sclerosis (MS) and the animal counterpart experimental autoimmune encephalomyelitis (EAE)Ageing Res Rev201841648129101043
- DasteADomblidesCGross-GoupilMImmune checkpoint inhibitors and elderly people: a reviewEur J Cancer20178215516628689093
- WuYJuQQianBZhangFShiHThe effectiveness of PD-1 inhibitors in non-small cell lung cancer (NSCLC) patients of different agesOncotarget2017987942794829487704
- SilvaIPLongGVSystemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practiceCurr Opin Oncol201729648449228914644
- WuYShiHJiangMThe clinical value of combination of immune checkpoint inhibitors in cancer patients: a meta-analysis of efficacy and safetyInt J Cancer2017141122562257028833119
- O’ReillyALarkinJThe safety of nivolumab for the treatment of metastatic melanomaExpert Opin Drug Saf201716895596128679287
- FerraraRMezquitaLAuclinEChaputNBesseBImmunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: does age really matter?Cancer Treat Rev201760606828889085
- RibasAKeffordRMarshallMAPhase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanomaJ Clin Oncol201331561662223295794
- HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
- RobertCThomasLBondarenkoIIpilimumab plus dacarbazine for previously untreated metastatic melanomaN Engl J Med2011364262517252621639810
- RobertCLongGVBradyBNivolumab in previously untreated melanoma without BRAF mutationN Engl J Med2015372432033025399552
- RibasAPuzanovIDummerRPembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialLancet Oncol201516890891826115796
- EliasRKarantanosTSiraEHartshornKLImmunotherapy comes of age: immune aging & checkpoint inhibitorsJ Geriatr Oncol20178322923528223073
- Czesnikiewicz-GuzikMLeeWWCuiDT cell subset-specific susceptibility to agingClin Immunol2008127110711818222733
- Grolleau-JuliusAHarningEKAbernathyLMYungRLImpaired dendritic cell function in aging leads to defective antitumor immunityCancer Res200868156341634918676859
- PlowdenJRenshaw-HoelscherMGangappaSEnglemanCKatzJMSambharaSImpaired antigen-induced CD8+ T cell clonal expansion in aging is due to defects in antigen presenting cell functionCell Immunol20042292869215474523
- GuoZTilburgsTWongBStromingerJLDysfunction of dendritic cells in aged C57BL/6 mice leads to failure of natural killer cell activation and of tumor eradicationProc Natl Acad Sci U S A201411139141991420425225399
- KeatingGMNivolumab: a review in advanced squamous non-small cell lung cancerDrugs201575161925193426514815
- NishijimaTFMussHBShacharSSMoschosSJComparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysisCancer Treat Rev201645303726946217